
Global mRNA Vaccines & Therapeutics Market Outlook and Growth Opportunities 2025
Description
Summary
According to APO Research, the global mRNA Vaccines & Therapeutics market is projected to grow from US$ million in 2025 to US$ million by 2031, at a compound annual growth rate (CAGR) of % during the forecast period.
The North American market for mRNA Vaccines & Therapeutics is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The Asia-Pacific market for mRNA Vaccines & Therapeutics is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
In China, the mRNA Vaccines & Therapeutics market is expected to rise from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The Europe market for mRNA Vaccines & Therapeutics is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Major global companies in the mRNA Vaccines & Therapeutics market include Translate Bio, Tiba Biotechnology, Sangamo Therapeutics, Moderna Therapeutics, In-Cell-Art, Ethris, eTheRNA, CureVac and BioNTech, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.
This report presents an overview of global market for mRNA Vaccines & Therapeutics, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2020 - 2024, estimates for 2025, and projections of CAGR through 2031.
This report researches the key producers of mRNA Vaccines & Therapeutics, also provides the sales of main regions and countries. Of the upcoming market potential for mRNA Vaccines & Therapeutics, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the mRNA Vaccines & Therapeutics sales, revenue, market share and industry ranking of main manufacturers, data from 2020 to 2025. Identification of the major stakeholders in the global mRNA Vaccines & Therapeutics market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2020 to 2031. Evaluation and forecast the market size for mRNA Vaccines & Therapeutics sales, projected growth trends, production technology, application and end-user industry.
mRNA Vaccines & Therapeutics Segment by Company
Translate Bio
Tiba Biotechnology
Sangamo Therapeutics
Moderna Therapeutics
In-Cell-Art
Ethris
eTheRNA
CureVac
BioNTech
Argos Therapeutics
mRNA Vaccines & Therapeutics Segment by Type
Infectious Disease Vaccines
Cancer Vaccines
mRNA Vaccines & Therapeutics Segment by Application
Infectious Disease
Cancer
mRNA Vaccines & Therapeutics Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Study Objectives
1. To analyze and research the global mRNA Vaccines & Therapeutics status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions mRNA Vaccines & Therapeutics market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify mRNA Vaccines & Therapeutics significant trends, drivers, influence factors in global and regions.
6. To analyze mRNA Vaccines & Therapeutics competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global mRNA Vaccines & Therapeutics market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of mRNA Vaccines & Therapeutics and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of mRNA Vaccines & Therapeutics.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Provides an overview of the mRNA Vaccines & Therapeutics market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2020-2031).
Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global mRNA Vaccines & Therapeutics industry.
Chapter 3: Detailed analysis of mRNA Vaccines & Therapeutics manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales and value of mRNA Vaccines & Therapeutics in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 7: Sales and value of mRNA Vaccines & Therapeutics in country level. It provides sigmate data by type, and by application for each country/region.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights.
According to APO Research, the global mRNA Vaccines & Therapeutics market is projected to grow from US$ million in 2025 to US$ million by 2031, at a compound annual growth rate (CAGR) of % during the forecast period.
The North American market for mRNA Vaccines & Therapeutics is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The Asia-Pacific market for mRNA Vaccines & Therapeutics is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
In China, the mRNA Vaccines & Therapeutics market is expected to rise from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The Europe market for mRNA Vaccines & Therapeutics is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Major global companies in the mRNA Vaccines & Therapeutics market include Translate Bio, Tiba Biotechnology, Sangamo Therapeutics, Moderna Therapeutics, In-Cell-Art, Ethris, eTheRNA, CureVac and BioNTech, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.
This report presents an overview of global market for mRNA Vaccines & Therapeutics, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2020 - 2024, estimates for 2025, and projections of CAGR through 2031.
This report researches the key producers of mRNA Vaccines & Therapeutics, also provides the sales of main regions and countries. Of the upcoming market potential for mRNA Vaccines & Therapeutics, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the mRNA Vaccines & Therapeutics sales, revenue, market share and industry ranking of main manufacturers, data from 2020 to 2025. Identification of the major stakeholders in the global mRNA Vaccines & Therapeutics market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2020 to 2031. Evaluation and forecast the market size for mRNA Vaccines & Therapeutics sales, projected growth trends, production technology, application and end-user industry.
mRNA Vaccines & Therapeutics Segment by Company
Translate Bio
Tiba Biotechnology
Sangamo Therapeutics
Moderna Therapeutics
In-Cell-Art
Ethris
eTheRNA
CureVac
BioNTech
Argos Therapeutics
mRNA Vaccines & Therapeutics Segment by Type
Infectious Disease Vaccines
Cancer Vaccines
mRNA Vaccines & Therapeutics Segment by Application
Infectious Disease
Cancer
mRNA Vaccines & Therapeutics Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Study Objectives
1. To analyze and research the global mRNA Vaccines & Therapeutics status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions mRNA Vaccines & Therapeutics market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify mRNA Vaccines & Therapeutics significant trends, drivers, influence factors in global and regions.
6. To analyze mRNA Vaccines & Therapeutics competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global mRNA Vaccines & Therapeutics market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of mRNA Vaccines & Therapeutics and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of mRNA Vaccines & Therapeutics.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Provides an overview of the mRNA Vaccines & Therapeutics market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2020-2031).
Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global mRNA Vaccines & Therapeutics industry.
Chapter 3: Detailed analysis of mRNA Vaccines & Therapeutics manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales and value of mRNA Vaccines & Therapeutics in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 7: Sales and value of mRNA Vaccines & Therapeutics in country level. It provides sigmate data by type, and by application for each country/region.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights.
Table of Contents
193 Pages
- 1 Market Overview
- 1.1 Product Definition
- 1.2 Global Market Growth Prospects
- 1.2.1 Global mRNA Vaccines & Therapeutics Sales Value (2020-2031)
- 1.2.2 Global mRNA Vaccines & Therapeutics Sales Volume (2020-2031)
- 1.2.3 Global mRNA Vaccines & Therapeutics Sales Average Price (2020-2031)
- 1.3 Assumptions and Limitations
- 1.4 Study Goals and Objectives
- 2 mRNA Vaccines & Therapeutics Market Dynamics
- 2.1 mRNA Vaccines & Therapeutics Industry Trends
- 2.2 mRNA Vaccines & Therapeutics Industry Drivers
- 2.3 mRNA Vaccines & Therapeutics Industry Opportunities and Challenges
- 2.4 mRNA Vaccines & Therapeutics Industry Restraints
- 3 mRNA Vaccines & Therapeutics Market by Company
- 3.1 Global mRNA Vaccines & Therapeutics Company Revenue Ranking in 2024
- 3.2 Global mRNA Vaccines & Therapeutics Revenue by Company (2020-2025)
- 3.3 Global mRNA Vaccines & Therapeutics Sales Volume by Company (2020-2025)
- 3.4 Global mRNA Vaccines & Therapeutics Average Price by Company (2020-2025)
- 3.5 Global mRNA Vaccines & Therapeutics Company Ranking (2023-2025)
- 3.6 Global mRNA Vaccines & Therapeutics Company Manufacturing Base and Headquarters
- 3.7 Global mRNA Vaccines & Therapeutics Company Product Type and Application
- 3.8 Global mRNA Vaccines & Therapeutics Company Establishment Date
- 3.9 Market Competitive Analysis
- 3.9.1 Global mRNA Vaccines & Therapeutics Market Concentration Ratio (CR5 and HHI)
- 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2024
- 3.9.3 2024 mRNA Vaccines & Therapeutics Tier 1, Tier 2, and Tier 3 Companies
- 3.10 Mergers and Acquisitions Expansion
- 4 mRNA Vaccines & Therapeutics Market by Type
- 4.1 mRNA Vaccines & Therapeutics Type Introduction
- 4.1.1 Infectious Disease Vaccines
- 4.1.2 Cancer Vaccines
- 4.2 Global mRNA Vaccines & Therapeutics Sales Volume by Type
- 4.2.1 Global mRNA Vaccines & Therapeutics Sales Volume by Type (2020 VS 2024 VS 2031)
- 4.2.2 Global mRNA Vaccines & Therapeutics Sales Volume by Type (2020-2031)
- 4.2.3 Global mRNA Vaccines & Therapeutics Sales Volume Share by Type (2020-2031)
- 4.3 Global mRNA Vaccines & Therapeutics Sales Value by Type
- 4.3.1 Global mRNA Vaccines & Therapeutics Sales Value by Type (2020 VS 2024 VS 2031)
- 4.3.2 Global mRNA Vaccines & Therapeutics Sales Value by Type (2020-2031)
- 4.3.3 Global mRNA Vaccines & Therapeutics Sales Value Share by Type (2020-2031)
- 5 mRNA Vaccines & Therapeutics Market by Application
- 5.1 mRNA Vaccines & Therapeutics Application Introduction
- 5.1.1 Infectious Disease
- 5.1.2 Cancer
- 5.2 Global mRNA Vaccines & Therapeutics Sales Volume by Application
- 5.2.1 Global mRNA Vaccines & Therapeutics Sales Volume by Application (2020 VS 2024 VS 2031)
- 5.2.2 Global mRNA Vaccines & Therapeutics Sales Volume by Application (2020-2031)
- 5.2.3 Global mRNA Vaccines & Therapeutics Sales Volume Share by Application (2020-2031)
- 5.3 Global mRNA Vaccines & Therapeutics Sales Value by Application
- 5.3.1 Global mRNA Vaccines & Therapeutics Sales Value by Application (2020 VS 2024 VS 2031)
- 5.3.2 Global mRNA Vaccines & Therapeutics Sales Value by Application (2020-2031)
- 5.3.3 Global mRNA Vaccines & Therapeutics Sales Value Share by Application (2020-2031)
- 6 mRNA Vaccines & Therapeutics Regional Sales and Value Analysis
- 6.1 Global mRNA Vaccines & Therapeutics Sales by Region: 2020 VS 2024 VS 2031
- 6.2 Global mRNA Vaccines & Therapeutics Sales by Region (2020-2031)
- 6.2.1 Global mRNA Vaccines & Therapeutics Sales by Region: 2020-2025
- 6.2.2 Global mRNA Vaccines & Therapeutics Sales by Region (2026-2031)
- 6.3 Global mRNA Vaccines & Therapeutics Sales Value by Region: 2020 VS 2024 VS 2031
- 6.4 Global mRNA Vaccines & Therapeutics Sales Value by Region (2020-2031)
- 6.4.1 Global mRNA Vaccines & Therapeutics Sales Value by Region: 2020-2025
- 6.4.2 Global mRNA Vaccines & Therapeutics Sales Value by Region (2026-2031)
- 6.5 Global mRNA Vaccines & Therapeutics Market Price Analysis by Region (2020-2025)
- 6.6 North America
- 6.6.1 North America mRNA Vaccines & Therapeutics Sales Value (2020-2031)
- 6.6.2 North America mRNA Vaccines & Therapeutics Sales Value Share by Country, 2024 VS 2031
- 6.7 Europe
- 6.7.1 Europe mRNA Vaccines & Therapeutics Sales Value (2020-2031)
- 6.7.2 Europe mRNA Vaccines & Therapeutics Sales Value Share by Country, 2024 VS 2031
- 6.8 Asia-Pacific
- 6.8.1 Asia-Pacific mRNA Vaccines & Therapeutics Sales Value (2020-2031)
- 6.8.2 Asia-Pacific mRNA Vaccines & Therapeutics Sales Value Share by Country, 2024 VS 2031
- 6.9 South America
- 6.9.1 South America mRNA Vaccines & Therapeutics Sales Value (2020-2031)
- 6.9.2 South America mRNA Vaccines & Therapeutics Sales Value Share by Country, 2024 VS 2031
- 6.10 Middle East & Africa
- 6.10.1 Middle East & Africa mRNA Vaccines & Therapeutics Sales Value (2020-2031)
- 6.10.2 Middle East & Africa mRNA Vaccines & Therapeutics Sales Value Share by Country, 2024 VS 2031
- 7 mRNA Vaccines & Therapeutics Country-level Sales and Value Analysis
- 7.1 Global mRNA Vaccines & Therapeutics Sales by Country: 2020 VS 2024 VS 2031
- 7.2 Global mRNA Vaccines & Therapeutics Sales Value by Country: 2020 VS 2024 VS 2031
- 7.3 Global mRNA Vaccines & Therapeutics Sales by Country (2020-2031)
- 7.3.1 Global mRNA Vaccines & Therapeutics Sales by Country (2020-2025)
- 7.3.2 Global mRNA Vaccines & Therapeutics Sales by Country (2026-2031)
- 7.4 Global mRNA Vaccines & Therapeutics Sales Value by Country (2020-2031)
- 7.4.1 Global mRNA Vaccines & Therapeutics Sales Value by Country (2020-2025)
- 7.4.2 Global mRNA Vaccines & Therapeutics Sales Value by Country (2026-2031)
- 7.5 USA
- 7.5.1 USA mRNA Vaccines & Therapeutics Sales Value Growth Rate (2020-2031)
- 7.5.2 USA mRNA Vaccines & Therapeutics Sales Value Share by Type, 2024 VS 2031
- 7.5.3 USA mRNA Vaccines & Therapeutics Sales Value Share by Application, 2024 VS 2031
- 7.6 Canada
- 7.6.1 Canada mRNA Vaccines & Therapeutics Sales Value Growth Rate (2020-2031)
- 7.6.2 Canada mRNA Vaccines & Therapeutics Sales Value Share by Type, 2024 VS 2031
- 7.6.3 Canada mRNA Vaccines & Therapeutics Sales Value Share by Application, 2024 VS 2031
- 7.7 Mexico
- 7.6.1 Mexico mRNA Vaccines & Therapeutics Sales Value Growth Rate (2020-2031)
- 7.6.2 Mexico mRNA Vaccines & Therapeutics Sales Value Share by Type, 2024 VS 2031
- 7.6.3 Mexico mRNA Vaccines & Therapeutics Sales Value Share by Application, 2024 VS 2031
- 7.8 Germany
- 7.8.1 Germany mRNA Vaccines & Therapeutics Sales Value Growth Rate (2020-2031)
- 7.8.2 Germany mRNA Vaccines & Therapeutics Sales Value Share by Type, 2024 VS 2031
- 7.8.3 Germany mRNA Vaccines & Therapeutics Sales Value Share by Application, 2024 VS 2031
- 7.9 France
- 7.9.1 France mRNA Vaccines & Therapeutics Sales Value Growth Rate (2020-2031)
- 7.9.2 France mRNA Vaccines & Therapeutics Sales Value Share by Type, 2024 VS 2031
- 7.9.3 France mRNA Vaccines & Therapeutics Sales Value Share by Application, 2024 VS 2031
- 7.10 U.K.
- 7.10.1 U.K. mRNA Vaccines & Therapeutics Sales Value Growth Rate (2020-2031)
- 7.10.2 U.K. mRNA Vaccines & Therapeutics Sales Value Share by Type, 2024 VS 2031
- 7.10.3 U.K. mRNA Vaccines & Therapeutics Sales Value Share by Application, 2024 VS 2031
- 7.11 Italy
- 7.11.1 Italy mRNA Vaccines & Therapeutics Sales Value Growth Rate (2020-2031)
- 7.11.2 Italy mRNA Vaccines & Therapeutics Sales Value Share by Type, 2024 VS 2031
- 7.11.3 Italy mRNA Vaccines & Therapeutics Sales Value Share by Application, 2024 VS 2031
- 7.12 Spain
- 7.12.1 Spain mRNA Vaccines & Therapeutics Sales Value Growth Rate (2020-2031)
- 7.12.2 Spain mRNA Vaccines & Therapeutics Sales Value Share by Type, 2024 VS 2031
- 7.12.3 Spain mRNA Vaccines & Therapeutics Sales Value Share by Application, 2024 VS 2031
- 7.13 Russia
- 7.13.1 Russia mRNA Vaccines & Therapeutics Sales Value Growth Rate (2020-2031)
- 7.13.2 Russia mRNA Vaccines & Therapeutics Sales Value Share by Type, 2024 VS 2031
- 7.13.3 Russia mRNA Vaccines & Therapeutics Sales Value Share by Application, 2024 VS 2031
- 7.14 Netherlands
- 7.14.1 Netherlands mRNA Vaccines & Therapeutics Sales Value Growth Rate (2020-2031)
- 7.14.2 Netherlands mRNA Vaccines & Therapeutics Sales Value Share by Type, 2024 VS 2031
- 7.14.3 Netherlands mRNA Vaccines & Therapeutics Sales Value Share by Application, 2024 VS 2031
- 7.15 Nordic Countries
- 7.15.1 Nordic Countries mRNA Vaccines & Therapeutics Sales Value Growth Rate (2020-2031)
- 7.15.2 Nordic Countries mRNA Vaccines & Therapeutics Sales Value Share by Type, 2024 VS 2031
- 7.15.3 Nordic Countries mRNA Vaccines & Therapeutics Sales Value Share by Application, 2024 VS 2031
- 7.16 China
- 7.16.1 China mRNA Vaccines & Therapeutics Sales Value Growth Rate (2020-2031)
- 7.16.2 China mRNA Vaccines & Therapeutics Sales Value Share by Type, 2024 VS 2031
- 7.16.3 China mRNA Vaccines & Therapeutics Sales Value Share by Application, 2024 VS 2031
- 7.17 Japan
- 7.17.1 Japan mRNA Vaccines & Therapeutics Sales Value Growth Rate (2020-2031)
- 7.17.2 Japan mRNA Vaccines & Therapeutics Sales Value Share by Type, 2024 VS 2031
- 7.17.3 Japan mRNA Vaccines & Therapeutics Sales Value Share by Application, 2024 VS 2031
- 7.18 South Korea
- 7.18.1 South Korea mRNA Vaccines & Therapeutics Sales Value Growth Rate (2020-2031)
- 7.18.2 South Korea mRNA Vaccines & Therapeutics Sales Value Share by Type, 2024 VS 2031
- 7.18.3 South Korea mRNA Vaccines & Therapeutics Sales Value Share by Application, 2024 VS 2031
- 7.19 India
- 7.19.1 India mRNA Vaccines & Therapeutics Sales Value Growth Rate (2020-2031)
- 7.19.2 India mRNA Vaccines & Therapeutics Sales Value Share by Type, 2024 VS 2031
- 7.19.3 India mRNA Vaccines & Therapeutics Sales Value Share by Application, 2024 VS 2031
- 7.20 Australia
- 7.20.1 Australia mRNA Vaccines & Therapeutics Sales Value Growth Rate (2020-2031)
- 7.20.2 Australia mRNA Vaccines & Therapeutics Sales Value Share by Type, 2024 VS 2031
- 7.20.3 Australia mRNA Vaccines & Therapeutics Sales Value Share by Application, 2024 VS 2031
- 7.21 Southeast Asia
- 7.21.1 Southeast Asia mRNA Vaccines & Therapeutics Sales Value Growth Rate (2020-2031)
- 7.21.2 Southeast Asia mRNA Vaccines & Therapeutics Sales Value Share by Type, 2024 VS 2031
- 7.21.3 Southeast Asia mRNA Vaccines & Therapeutics Sales Value Share by Application, 2024 VS 2031
- 7.22 Brazil
- 7.22.1 Brazil mRNA Vaccines & Therapeutics Sales Value Growth Rate (2020-2031)
- 7.22.2 Brazil mRNA Vaccines & Therapeutics Sales Value Share by Type, 2024 VS 2031
- 7.22.3 Brazil mRNA Vaccines & Therapeutics Sales Value Share by Application, 2024 VS 2031
- 7.23 Argentina
- 7.23.1 Argentina mRNA Vaccines & Therapeutics Sales Value Growth Rate (2020-2031)
- 7.23.2 Argentina mRNA Vaccines & Therapeutics Sales Value Share by Type, 2024 VS 2031
- 7.23.3 Argentina mRNA Vaccines & Therapeutics Sales Value Share by Application, 2024 VS 2031
- 7.24 Chile
- 7.24.1 Chile mRNA Vaccines & Therapeutics Sales Value Growth Rate (2020-2031)
- 7.24.2 Chile mRNA Vaccines & Therapeutics Sales Value Share by Type, 2024 VS 2031
- 7.24.3 Chile mRNA Vaccines & Therapeutics Sales Value Share by Application, 2024 VS 2031
- 7.25 Colombia
- 7.25.1 Colombia mRNA Vaccines & Therapeutics Sales Value Growth Rate (2020-2031)
- 7.25.2 Colombia mRNA Vaccines & Therapeutics Sales Value Share by Type, 2024 VS 2031
- 7.25.3 Colombia mRNA Vaccines & Therapeutics Sales Value Share by Application, 2024 VS 2031
- 7.26 Peru
- 7.26.1 Peru mRNA Vaccines & Therapeutics Sales Value Growth Rate (2020-2031)
- 7.26.2 Peru mRNA Vaccines & Therapeutics Sales Value Share by Type, 2024 VS 2031
- 7.26.3 Peru mRNA Vaccines & Therapeutics Sales Value Share by Application, 2024 VS 2031
- 7.27 Saudi Arabia
- 7.27.1 Saudi Arabia mRNA Vaccines & Therapeutics Sales Value Growth Rate (2020-2031)
- 7.27.2 Saudi Arabia mRNA Vaccines & Therapeutics Sales Value Share by Type, 2024 VS 2031
- 7.27.3 Saudi Arabia mRNA Vaccines & Therapeutics Sales Value Share by Application, 2024 VS 2031
- 7.28 Israel
- 7.28.1 Israel mRNA Vaccines & Therapeutics Sales Value Growth Rate (2020-2031)
- 7.28.2 Israel mRNA Vaccines & Therapeutics Sales Value Share by Type, 2024 VS 2031
- 7.28.3 Israel mRNA Vaccines & Therapeutics Sales Value Share by Application, 2024 VS 2031
- 7.29 UAE
- 7.29.1 UAE mRNA Vaccines & Therapeutics Sales Value Growth Rate (2020-2031)
- 7.29.2 UAE mRNA Vaccines & Therapeutics Sales Value Share by Type, 2024 VS 2031
- 7.29.3 UAE mRNA Vaccines & Therapeutics Sales Value Share by Application, 2024 VS 2031
- 7.30 Turkey
- 7.30.1 Turkey mRNA Vaccines & Therapeutics Sales Value Growth Rate (2020-2031)
- 7.30.2 Turkey mRNA Vaccines & Therapeutics Sales Value Share by Type, 2024 VS 2031
- 7.30.3 Turkey mRNA Vaccines & Therapeutics Sales Value Share by Application, 2024 VS 2031
- 7.31 Iran
- 7.31.1 Iran mRNA Vaccines & Therapeutics Sales Value Growth Rate (2020-2031)
- 7.31.2 Iran mRNA Vaccines & Therapeutics Sales Value Share by Type, 2024 VS 2031
- 7.31.3 Iran mRNA Vaccines & Therapeutics Sales Value Share by Application, 2024 VS 2031
- 7.32 Egypt
- 7.32.1 Egypt mRNA Vaccines & Therapeutics Sales Value Growth Rate (2020-2031)
- 7.32.2 Egypt mRNA Vaccines & Therapeutics Sales Value Share by Type, 2024 VS 2031
- 7.32.3 Egypt mRNA Vaccines & Therapeutics Sales Value Share by Application, 2024 VS 2031
- 8 Company Profiles
- 8.1 Translate Bio
- 8.1.1 Translate Bio Comapny Information
- 8.1.2 Translate Bio Business Overview
- 8.1.3 Translate Bio mRNA Vaccines & Therapeutics Sales, Value and Gross Margin (2020-2025)
- 8.1.4 Translate Bio mRNA Vaccines & Therapeutics Product Portfolio
- 8.1.5 Translate Bio Recent Developments
- 8.2 Tiba Biotechnology
- 8.2.1 Tiba Biotechnology Comapny Information
- 8.2.2 Tiba Biotechnology Business Overview
- 8.2.3 Tiba Biotechnology mRNA Vaccines & Therapeutics Sales, Value and Gross Margin (2020-2025)
- 8.2.4 Tiba Biotechnology mRNA Vaccines & Therapeutics Product Portfolio
- 8.2.5 Tiba Biotechnology Recent Developments
- 8.3 Sangamo Therapeutics
- 8.3.1 Sangamo Therapeutics Comapny Information
- 8.3.2 Sangamo Therapeutics Business Overview
- 8.3.3 Sangamo Therapeutics mRNA Vaccines & Therapeutics Sales, Value and Gross Margin (2020-2025)
- 8.3.4 Sangamo Therapeutics mRNA Vaccines & Therapeutics Product Portfolio
- 8.3.5 Sangamo Therapeutics Recent Developments
- 8.4 Moderna Therapeutics
- 8.4.1 Moderna Therapeutics Comapny Information
- 8.4.2 Moderna Therapeutics Business Overview
- 8.4.3 Moderna Therapeutics mRNA Vaccines & Therapeutics Sales, Value and Gross Margin (2020-2025)
- 8.4.4 Moderna Therapeutics mRNA Vaccines & Therapeutics Product Portfolio
- 8.4.5 Moderna Therapeutics Recent Developments
- 8.5 In-Cell-Art
- 8.5.1 In-Cell-Art Comapny Information
- 8.5.2 In-Cell-Art Business Overview
- 8.5.3 In-Cell-Art mRNA Vaccines & Therapeutics Sales, Value and Gross Margin (2020-2025)
- 8.5.4 In-Cell-Art mRNA Vaccines & Therapeutics Product Portfolio
- 8.5.5 In-Cell-Art Recent Developments
- 8.6 Ethris
- 8.6.1 Ethris Comapny Information
- 8.6.2 Ethris Business Overview
- 8.6.3 Ethris mRNA Vaccines & Therapeutics Sales, Value and Gross Margin (2020-2025)
- 8.6.4 Ethris mRNA Vaccines & Therapeutics Product Portfolio
- 8.6.5 Ethris Recent Developments
- 8.7 eTheRNA
- 8.7.1 eTheRNA Comapny Information
- 8.7.2 eTheRNA Business Overview
- 8.7.3 eTheRNA mRNA Vaccines & Therapeutics Sales, Value and Gross Margin (2020-2025)
- 8.7.4 eTheRNA mRNA Vaccines & Therapeutics Product Portfolio
- 8.7.5 eTheRNA Recent Developments
- 8.8 CureVac
- 8.8.1 CureVac Comapny Information
- 8.8.2 CureVac Business Overview
- 8.8.3 CureVac mRNA Vaccines & Therapeutics Sales, Value and Gross Margin (2020-2025)
- 8.8.4 CureVac mRNA Vaccines & Therapeutics Product Portfolio
- 8.8.5 CureVac Recent Developments
- 8.9 BioNTech
- 8.9.1 BioNTech Comapny Information
- 8.9.2 BioNTech Business Overview
- 8.9.3 BioNTech mRNA Vaccines & Therapeutics Sales, Value and Gross Margin (2020-2025)
- 8.9.4 BioNTech mRNA Vaccines & Therapeutics Product Portfolio
- 8.9.5 BioNTech Recent Developments
- 8.10 Argos Therapeutics
- 8.10.1 Argos Therapeutics Comapny Information
- 8.10.2 Argos Therapeutics Business Overview
- 8.10.3 Argos Therapeutics mRNA Vaccines & Therapeutics Sales, Value and Gross Margin (2020-2025)
- 8.10.4 Argos Therapeutics mRNA Vaccines & Therapeutics Product Portfolio
- 8.10.5 Argos Therapeutics Recent Developments
- 9 Value Chain and Sales Channels Analysis
- 9.1 mRNA Vaccines & Therapeutics Value Chain Analysis
- 9.1.1 mRNA Vaccines & Therapeutics Key Raw Materials
- 9.1.2 Raw Materials Key Suppliers
- 9.1.3 Manufacturing Cost Structure
- 9.1.4 mRNA Vaccines & Therapeutics Sales Mode & Process
- 9.2 mRNA Vaccines & Therapeutics Sales Channels Analysis
- 9.2.1 Direct Comparison with Distribution Share
- 9.2.2 mRNA Vaccines & Therapeutics Distributors
- 9.2.3 mRNA Vaccines & Therapeutics Customers
- 10 Concluding Insights
- 11 Appendix
- 11.1 Reasons for Doing This Study
- 11.2 Research Methodology
- 11.3 Research Process
- 11.4 Authors List of This Report
- 11.5 Data Source
- 11.5.1 Secondary Sources
- 11.5.2 Primary Sources
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.